Skip NavigationSkip to Content

A mutational comparison of adult and adolescent and young adult (AYA) colon cancer

  1. Author:
    Tricoli, James V [ORCID]
    Boardman, Lisa A [ORCID]
    Patidar, Rajesh
    Sindiri, Sivasish
    Jang, Jin S
    Walsh, William
    McGregor, Paul M
    Camalier, Corinne
    Mehaffey, Michele G
    Furman, Wayne L
    Bahrami, Armita
    Williams, Mickey
    Lih, Chih-Jian
    Conley, Barbara A
    Khan, Javed
  2. Author Address

    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Molecular Characterization and Assay Development Laboratory, Leidos, Frederick, Maryland., Department of Hematology/Oncology, St. Jude Children 39;s Research Hospital, Memphis, Tennessee., Department of Pathology, St. Jude Children 39;s Research Hospital, Memphis, Tennessee.,
    1. Year: 2018
    2. Date: Mar 1
    3. Epub Date: 2017 11 30
  1. Journal: Cancer
    1. 124
    2. 5
    3. Pages: 1070-1082
  2. Type of Article: Article
  1. Abstract:

    It is possible that the relative lack of progress in treatment outcomes among adolescent and young adult (AYA) patients with cancer is caused by a difference in disease biology compared with the corresponding diseases in younger and older individuals. There is evidence that colon cancer is more aggressive and has a poorer prognosis in AYA patients than in older adult patients. To further understand the molecular basis for this difference, whole-exome sequencing was conducted on a cohort of 30 adult, 30 AYA, and 2 pediatric colon cancers. A statistically significant difference in mutational frequency was observed between AYA and adult samples in 43 genes, including ROBO1, MYC binding protein 2 (MYCBP2), breast cancer 2 (early onset) (BRCA2), MAP3K3, MCPH1, RASGRP3, PTCH1, RAD9B, CTNND1, ATM, NF1; KIT, PTEN, and FBXW7. Many of these mutations were nonsynonymous, missense, stop-gain, or frameshift mutations that were damaging. Next, RNA sequencing was performed on a subset of the samples to confirm the mutations identified by exome sequencing. This confirmation study verified the presence of a significantly greater frequency of damaging mutations in AYA compared with adult colon cancers for 5 of the 43 genes (MYCBP2, BRCA2, PHLPP1, TOPORS, and ATR). The current results provide the rationale for a more comprehensive study with a larger sample set and experimental validation of the functional impact of the identified variants along with their contribution to the biologic and clinical characteristics of AYA colon cancer. Cancer 2017. © 2017 American Cancer Society. © 2017 American Cancer Society.

    See More

External Sources

  1. DOI: 10.1002/cncr.31136
  2. PMID: 29194591
  3. PMCID: PMC5821537
  4. WOS: 000425729100026

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel